We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Forest Laboratories has decided to bury the hatchet with Teva Pharmaceuticals USA and Mayne Pharma, settling a two-and-a-half year-long patent dispute for undisclosed terms. Read More
The UK’s drug pricing watchdog is recommending NHS reimburse for Servier’s metastatic colorectal cancer drug Lonsurf, provided the company offers the drug at a discounted price. Read More
Xellia Pharmaceuticals and the FDA have agreed on a modified consent decree so Xellia can resume manufacturing at the Bedford, Ohio, site it purchased from Ben Venue Laboratories. Read More
A Delaware federal court ruled that Mylan’s efforts to develop a generic version of Forest Laboratories’ Savella infringed on three of the company’s patents. Read More